23andme, Inc.

Tina Thai

Chingwei Vivian Lee

Germaine Fuh-Kelly

Louise Scharf

Krista Maureen McCutcheon

Yu Chen

Shouhua Xiao

Yao-ming Huang

Samuel Nalle

Valentine Yeung

Augusta Eleanor Broughton

Navneet Singh

Zuoan Yi

Erik E Karrer

Ashka Bharat Patel

Shashank Bharill

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.

Anti-CD96 antibodies and methods of use thereof

The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36α, IL-36β, and/or IL-36γ, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.

Anti-IL-36 antibodies and methods of use thereof

Growing community of inventors

San Mateo, CA, United States of America

Tina Thai